Stryker (NYSE:SYK) Upgraded by BMO Capital Markets to “Strong-Buy” Rating

Stryker (NYSE:SYK – Get Free Report) was upgraded by equities research analysts at BMO Capital Markets to a “strong-buy” rating in a research note issued to investors on Wednesday,Zacks.com reports.

SYK has been the topic of several other reports. Sanford C. Bernstein set a $410.00 price objective on shares of Stryker in a report on Friday, May 1st. Wall Street Zen cut shares of Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings downgraded shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 4th. Robert W. Baird set a $385.00 price target on Stryker in a research note on Friday, May 1st. Finally, Argus set a $370.00 price objective on Stryker in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $392.87.

Get Stryker alerts:

Read Our Latest Report on SYK

Stryker Stock Performance

SYK opened at $326.87 on Wednesday. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. Stryker has a 12-month low of $281.00 and a 12-month high of $404.87. The business has a 50 day moving average of $309.82 and a 200-day moving average of $338.02. The stock has a market cap of $125.31 billion, a price-to-earnings ratio of 37.83, a PEG ratio of 2.09 and a beta of 0.77.

Stryker (NYSE:SYK – Get Free Report) last posted its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same period in the previous year, the firm posted $2.84 earnings per share. The firm’s revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities research analysts expect that Stryker will post 14.98 earnings per share for the current year.

Insider Buying and Selling at Stryker

In other news, VP M Kathryn Fink sold 5,220 shares of Stryker stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.85, for a total value of $1,481,697.00. Following the transaction, the vice president owned 13,137 shares in the company, valued at approximately $3,728,937.45. This trade represents a 28.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This trade represents a 13.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 323,264 shares of company stock worth $100,659,489 over the last three months. Corporate insiders own 4.60% of the company’s stock.

Institutional Investors Weigh In On Stryker

Hedge funds have recently made changes to their positions in the stock. Godfrey Financial Associates Inc. acquired a new position in shares of Stryker during the fourth quarter worth $26,000. Sankala Group LLC acquired a new stake in shares of Stryker during the fourth quarter valued at about $26,000. United Financial Planning Group LLC bought a new stake in shares of Stryker during the third quarter worth about $27,000. Atlas Capital Advisors Inc. acquired a new position in shares of Stryker in the fourth quarter valued at approximately $27,000. Finally, DJE Kapital AG bought a new position in Stryker in the 4th quarter valued at approximately $28,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

About Stryker

(Get Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Featured Stories

• Five stocks we like better than Stryker
• PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
• Dollar Tree’s Turnaround Is Starting to Take Root
• Why Levi’s Digital Strategy Is Paying Off in a Big Way
• Constellation Brands: Beer Growth and Buybacks Mask Stock’s Slump

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.